|Mr. Geoff MacKay BSc||Co- Founder, Pres, CEO & Director||754.39k||N/A||1966|
|Mr. Erik John Ostrowski M.B.A.||CFO & Treasurer||554.66k||N/A||1973|
|Mr. Jeffrey Medin Ph.D.||Scientific Founder||N/A||N/A||N/A|
|Mr. Matthew Arnold||Head of Operations||N/A||N/A||N/A|
|Mr. Steven N. Avruch J.D.||Chief Legal Officer & Sec.||N/A||N/A||1961|
|Ms. Monique Da Silva||Sr. VP of Corp. Communications||N/A||N/A||N/A|
|Ms. Deanna M. Petersen MBA||Chief Bus. Officer||N/A||N/A||1962|
|Ms. Azadeh Golipour Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Andreas Kouri||Sr. VP of Global Supply Chain & External Manufacturing||N/A||N/A||N/A|
|Dr. Essra Ridha FFPM, M.D.||Chief Medical Officer||N/A||N/A||N/A|
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 9.